journal
MENU ▼
Read by QxMD icon Read
search

Clinical Pharmacology and Therapeutics

journal
https://www.readbyqxmd.com/read/28748631/reverse-translation-for-assessment-of-confidence-in-animal-models-of-multiple-sclerosis-for-drug-discovery
#1
REVIEW
Bert A 't Hart, Jon D Laman, Yolanda S Kap
No abstract text is available yet for this article.
July 27, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28744905/pnpla3-rs738409-and-hepatotoxicity-in-children-with-b-cell-acute-lymphoblastic-leukemia-a-validation-study-in-a-spanish-cohort
#2
LETTER
A Gutierrez-Camino, I Martin-Guerrero, A Garcia-Orad
No abstract text is available yet for this article.
July 26, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28744849/response-to-pnpla3-rs738409-and-hepatotoxicity-in-children-with-b-cell-acute-lymphoblastic-leukemia-a-validation-study-in-a-spanish-cohort
#3
LETTER
Y Liu, C A Fernandez, M V Relling
No abstract text is available yet for this article.
July 26, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28738449/pbpk-modeling-of-the-effect-of-reduced-kidney-function-on-the-pharmacokinetics-of-drugs-excreted-renally-by-organic-anion-transporters
#4
C-H Hsueh, V Hsu, P Zhao, L Zhang, K M Giacomini, S-M Huang
Altered pharmacokinetics (PK) in subjects with chronic kidney disease (CKD) may lead to dosing adjustment of certain drugs in subjects with CKD. It can be valuable to quantitatively predict PK in CKD for the management of drug dosing in these subjects. We developed physiologically based pharmacokinetic (PBPK) models of seven renally eliminated drugs: adefovir, avibactam, entecavir, famotidine, ganciclovir, oseltamivir carboxylate, and sitagliptin. These drugs are all substrates of renal organic anion transporters (OATs)...
July 24, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28736931/genetic-variants-in-hsd17b3-smad3-and-ipo11-impact-circulating-lipids-in-response-to-fenofibrate-in-individuals-with-type-2-diabetes
#5
Daniel M Rotroff, Sonja S Pijut, Skylar W Marvel, John R Jack, Tammy M Havener, Aurora Pujol, Agatha Schluter, Greg A Graf, Henry N Ginsberg, Hetal S Shah, He Gao, Mario-Luca Morieri, Alessandro Doria, Josyf C Mychaleckyi, Howard L McLeod, John B Buse, Michael J Wagner, Alison A Motsinger-Reif
Individuals with type 2 diabetes (T2D) and dyslipidemia are at an increased risk of cardiovascular disease. Fibrates are a class of drugs prescribed to treat dyslipidemia, but variation in response has been observed. To evaluate common and rare genetic variants that impact lipid responses to fenofibrate in statin-treated T2D patients, we examined lipid changes in response to fenofibrate therapy using genome-wide association(GWA). Associations were followed-up using gene expression studies in mice. Common variants in SMAD3 and IPO11 were marginally associated with lipid changes in black subjects(p<5x10(-6) )...
July 24, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28736918/phase-1-randomized-double-blind-placebo-controlled-single-dose-and-multiple-dose-studies-of-erenumab-in-healthy-subjects-and-patients-with-migraine
#6
Jan de Hoon, Anne Van Hecken, Corinne Vandermeulen, Lucy Yan, Brian Smith, Jiyun Sunny Chen, Edgar Bautista, Lisa Hamilton, Javier Waksman, Thuy Vu, Gabriel Vargas
Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor. We report the data from two phase 1 studies assessing the safety, pharmacokinetics (PK), and pharmacodynamics of single and multiple administrations of erenumab in healthy subjects and patients with migraine. The results indicate that the PK profile of erenumab is nonlinear from 1 mg to 70 mg and the linear portion of the clearance from 70 mg to 210 mg is consistent with other human immunoglobulin (Ig)G2 antibodies...
July 24, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28731221/evaluating-the-renal-safety-of-investigational-new-drugs-where-should-we-be-going
#7
N Stockbridge, M Blank, E A Hausner, A Thompson
We the authors work in the US Food and Drug Administration (FDA) review division responsible for the therapeutic agents for primary renal disease. We also field consultative inquiries regarding off-target adverse renal effects of drugs intended to treat other diseases. We do neither basic science research on renal diseases nor clinical studies of new drugs, but we are professional spectators of both. We offer here our thoughts on the challenge of identifying renal safety signals in the preclinical space and in the earliest phases of clinical development...
July 21, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28722146/implementing-clinical-prediction-models-pushing-the-needle-towards-precision-pharmacotherapy
#8
S R Dorajoo, A Chan
Clinical prediction models promise a future of precision drug therapy. However, very few models are used in practice. Although models can eliminate unwanted clinical guesswork, several barriers hinder model implementation in practice. Here we discuss the less well-recognized barriers hindering model implementation for precision prescribing, highlighting areas that warrant attention, primarily relating to ethical and regulatory considerations that are requisite in paving the way towards a future of precision pharmacotherapy...
July 19, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28722123/value-of-biomarkers-in-the-prevention-of-rheumatoid-arthritis
#9
A Finckh, D Alpizar-Rodriguez, P Roux-Lombard
Recent diagnostic advances allow to identify persons in a pre-symptomatic stage of rheumatoid arthritis (RA), opening the way for a preventive therapeutic intervention, which may potentially be curative. We review and discuss existing biomarkers predictive of future onset of RA. A responsible use of biomarkers in clinical settings will require an integration of blood-based tests, imaging techniques, clinical history, environmental risk factors, and family history.
July 19, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28710775/cyclooxygenase-inhibition-pain-inflammation-and-the-cardiovascular-system
#10
Tilo Grosser, Katherine N Theken, Garret A FitzGerald
Inhibitors of the cyclooxygenases (COXs), the non-steroidal antiinflammatory drugs (NSAIDs), relieve inflammatory pain, but are associated with gastrointestinal and cardiovascular complications. Given the widespread use of NSAIDs there has been a longstanding interest in optimizing their risk-benefit ratio for example by reducing the gastrointestinal risk. More recently, the focus has shifted toward the cardiovascular complications of NSAIDs and very large prospective studies have been performed to compare cardiovascular risk across distinct NSAIDs...
July 14, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28707341/impact-of-hyperkalemia-and-worsening-renal-function-on-the-use-of-renin-angiotensin-aldosterone-system-inhibitors-in-chronic-heart-failure-with-reduced-ejection-fraction
#11
B Pitt, P Rossignol
Patients with heart failure (HF) and reduced ejection fraction (HFREF) are at increased risk of death and hospitalizations for HF. Numerous registries have reported a large and persistent gap between real-life practice in the use of life-saving evidence-based therapies, such as renin angiotensin system inhibitors, beta blockers, mineralocorticoid receptor antagonists (MRAs), and recommended practices in international guidelines. The fears of inducing hyperkalemia and/or worsening renal function are the main triggers of this underuse...
July 14, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28699267/lucerastat-an-iminosugar-for-substrate-reduction-therapy-tolerability-pharmacodynamics-and-pharmacokinetics-in-patients-with-fabry-disease-on-enzyme-replacement
#12
N Guérard, D Oder, P Nordbeck, C Zwingelstein, O Morand, Rwd Welford, J Dingemanse, C Wanner
Lucerastat is a glucosylceramide synthase inhibitor aimed at reducing production of glycosphingolipids (GSLs), including those accumulating in Fabry disease (FD). The safety, tolerability, pharmacodynamics, and pharmacokinetics of oral lucerastat were evaluated in an exploratory study in FD patients. In this single-center, open-label, randomized study, 10 subjects received lucerastat 1000 mg b.i.d. for 12 weeks on top of enzyme replacement therapy (ERT) (lucerastat group). Four subjects with FD received ERT only...
July 12, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28699217/infection-risk-with-biologic-therapy-in-patients-with-inflammatory-bowel-disease
#13
REVIEW
Pieter Hindryckx, Gregor Novak, Stefanos Bonovas, Laurent Peyrin-Biroulet, Silvio Danese
No abstract text is available yet for this article.
July 12, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28699186/cancer-related-systemic-inflammation-the-challenges-and-therapeutic-opportunities-for-personalized-medicine
#14
Diana Shinko, Connie I Diakos, Stephen J Clarke, Kellie A Charles
Over the last decade there has been significant progress towards the development of personalized or "precision" medicine for many patients with cancer. However, there still remain sub-populations of cancer patients that do not possess a tumor mutation profile that is successfully targeted by the newer molecular anti-cancer drugs and further personalized approaches are needed. The presence of cancer-related systemic inflammation represents an under-appreciated sub-population of cancer patients needing personalized therapy...
July 12, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28699167/raising-standards-for-the-evaluation-of-future-psoriasis-therapeutics-a-critical-checklist
#15
REVIEW
Zenas Z N Yiu, Richard B Warren
No abstract text is available yet for this article.
July 12, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28699160/practical-recommendations-for-therapeutic-drug-monitoring-of-kinase-inhibitors-in-oncology
#16
REVIEW
R B Verheijen, H Yu, J H M Schellens, J H Beijnen, N Steeghs, A D R Huitema
No abstract text is available yet for this article.
July 12, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28699158/precision-medicine-in-inflammatory-bowel-diseases
#17
Sarah Fischer, Markus F Neurath
Inflammatory bowel diseases (IBD) are a lifelong condition of chronic, recurrent inflammation in the gut. The introduction of immunomodulators and biologic agents markedly improved the treatment of IBD. Therefore the use of biologics became an essential element in the rational therapy of IBD. Various substances are currently evaluated in clinical trials, addressing different target structures and offering further approaches in the field of IBD. Regarding the growing number of treatment options, the need for prediction of therapy response became a necessity and is subject of present research...
July 12, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28695658/fecal-microbial-transplantation-in-inflammatory-bowel-disease-a-movement-too-big-to-be-ignored
#18
M Laffin, K L Madsen
The development of new therapies for inflammatory bowel disease is plagued by high costs, potential side effects, and variable levels of effectiveness. Fecal microbial transplant in inflammatory bowel diseases can offer an alternative to traditionally developed pharmacologic therapies and has demonstrated the ability to induce disease remission in randomized control trials. However, questions remain about the ultimate role of this therapy in disease management, including long term safety, and the optimal composition of transplanted stool...
July 10, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28675460/real-life-use-of-anticoagulants-in-venous-thromboembolism-with-focus-on-patients-with-exclusion-criteria-for-direct-oral-anticoagulants
#19
Farès Moustafa, Raffaele Pesavento, Pierpaolo Di Micco, José González-Martínez, Roberto Quintavalla, Maria-Luisa Peris, José Antonio Porras, Nicolas Falvo, Pilar Baños, Manuel Monreal
We assessed the real-life use of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016, 3578 of 18853 patients (19%) had exclusion criteria. Irrespective of which anticoagulant was chosen, they had more VTE recurrences (hazard ratio [HR]: 3.10; 95%CI: 2.47-3.88), major bleeds (HR: 4.10; 95%CI: 3.38-4.96) and deaths (HR: 9.47; 95%CI: 8.46-10.6) than those without exclusion criteria. During initial therapy, no patient with exclusion criteria on DOACs (n=115) recurred, but those on rivaroxaban bled less often (adjusted HR: 0...
July 4, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28675423/poly-pharmacokinetic-study-of-a-multicomponent-herbal-medicine-in-healthy-chinese-volunteers
#20
Guoxiang Xie, Shouli Wang, Hua Zhang, Aihua Zhao, Jiajian Liu, Yueming Ma, Ke Lan, Yan Ni, Changxiao Liu, Ping Liu, Tianlu Chen, Wei Jia
The advent of mass spectrometry based analytical technologies coupled with multivariate statistical methods offers tremendous new opportunities for understanding the pharmacokinetics (PK) of multicomponent herbal medicines (HMs). We recently proposed a Poly-PK strategy to characterize the concentration-time profile and the metabolic response profile of multicomponent HMs, using an integrated phytochemical and metabolomics approach. Here, we provided the first example of the Poly-PK strategy, where we simultaneously characterized the PK as well as the metabolic response profiles of a Chinese herbal medicine, Huangqi decoction (HQD, consisting of Radix Astragali and Radix Glycyrrhizae), in healthy Chinese volunteers...
July 4, 2017: Clinical Pharmacology and Therapeutics
journal
journal
23600
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"